arrow
A

Alina S. Gerrie

University of British Columbia
H指数:28
被引数:2,578

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term survival and cause-specific mortality after event-free survival at 24 months (EFS24) in mantle cell lymphoma: an international multicohort study

套细胞淋巴瘤在24个月无事件生存期(EFS24)后的长期生存和特定病因死亡率:一项国际多队列研究

2026-09-220
OAAI
LySeqST: A targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma

LySeqST:一种用于弥漫性大B细胞淋巴瘤稳健基因组分类的靶向测序检测方法

2026-04-170
OAAI
Population-Wide Introduction of Dose-Adjusted EPOCH-R In High-grade B-cell Lymphoma with MYC/BCL2 Rearrangements, DLBCL Morphology

在高MYC/BCL2易位的弥漫大B细胞淋巴瘤中,进行剂量调整的EPOCH-R方案的群体推广,该淋巴瘤具有DLBCL形态。

2025-10-170
OAAI
Feasibility of Bruton’s Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient Perspective

Bruton’s Tyrosine Kinase 抑制剂停药在慢性淋巴细胞白血病中的可行性:患者的视角

2025-05-160
PRE
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Terry Fox Research Institute马拉松希望癌症中心网络:一项全加拿大的精准肿瘤学倡议

2025-04-010
PRE
BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma

Gutmair K,Villa D,Cunningham N,Silkenstedt E,Rimsza LM,Ramsower CA,Scott,D.W.,Gerrie,A.S.,Kluin-Nelemans,H.C.,Dreyling M,Hoster E.。BR或R-CHOP诱导联合利妥昔单抗维持治疗未经治疗、不适合移植的套细胞淋巴瘤患者。Blood Adv. 2025.9(9), 2302, 2306.

2025-01-010
OA
Biological and Prognostic Subgroups of Plasmablastic Lymphoma Defined By EBV Status and MYC Rearrangement- an LLMPP Study

根据EBV状态和MYC重排定义的浆细胞样淋巴瘤的生物与预后亚组——一项LLMPP研究

BLOOD
IF23.1
2024-11-050
PRE
Feasibility of Discontinuation of Bruton's Tyrosine Kinase Inhibitors in Patients with Chronic Lymphocytic Leukemia: A Patient Survey

慢性淋巴细胞白血病患者停用布托替尼酪氨酸激酶抑制剂的可行性:一项患者调查

BLOOD
IF23.1
2024-11-050
PRE
Richter Transformation (RT) in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Comparison of Two Eras

慢性淋巴细胞白血病(CLL)和小淋巴细胞淋巴瘤(SLL)中的里希特转化(RT):两个时代的比较

BLOOD
IF23.1
2024-11-050
PRE
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
2023-12-135
OAAI
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy
2021-12-0728
OAAI